| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
Purity: ≥98%
Ammonium pyrrolidine dithiocarbamate (also abbreviated as PDTC) is a potent nuclear factor-κB (NF-κB) inhibitor. It acts by inhibiting IκB phosphorylation, blocking NF-κB translocation to the nucleus, and suppressing the expression of cytokines that are expressed downstream. Pyrrolidinedithiocarbamate induces apoptosis in human acute myelogenous leukemic cells, which affects NF-κB activity, and attenuates bleomycin-induced pulmonary fibrosis in rats. Intestinal epithelial cells' production of IL-8 and NF-B activation are both inhibited by pyrrolidinedithiocarbamate.
| Targets |
NF-κB
|
|---|---|
| ln Vitro |
Pyrrolidinedithiocarbamate ammonium (Ammonium pyrrolidinedithiocarbamate; 3-1000 μM) pretreatment of cells inhibits IL-8 production in a dose-dependent manner[1].
Additionally, pyrrolidinedithiocarbamate ammonium (100 μM) inhibits IL-8 mRNA accumulation[1]. Because it blocks both NF-κB DNA binding and NF-κB-dependent transcriptional activity, pyrrolidinedithiocarbamate ammonium prevents NF-κB from becoming activated. The production of IL-8 by intestinal epithelial cells is decreased by NF-κB inhibition using pyrrolidinedithiocarbamate ammonium[1]. |
| ln Vivo |
Intestinal shortening is suppressed, and the DAI score is lower in the DSS+pyrrolidinedithiocarbamate ammonium-treated group II. The group II treated with DSS and pyrrolidinedithiocarbamate ammonium has significantly lower levels of activated NF-κB level and IL-1β and TNF-α. According to these findings, pyrrolidinedithiocarbamate ammonium can significantly reduce colitis by suppressing the expression of inflammatory cytokines (IL-1β and TNF-α), but it can also delay the healing of mucosal tissue defects (erosions or ulcers) brought on by inflammation. For the treatment of ulcerative colitis, pyrrolidinedithiocarbamate ammonium is helpful[2].
|
| Cell Assay |
The human colon cancer cell line HT-29 is obtained, and cells are grown in a modified McCoy's 5A medium supplemented with 10% fetal bovine serum. HT-29 cells in 96-well plates are stimulated with 20 ng/mL of IL-1β for 18 hours in order to examine the impact of pyrrolidinedithiocarbamate ammonium on IL-8 production. Thirty minutes before IL-1β stimulation, the cells are given different concentrations (3–1000 μM) of pyrrolidinedithiocarbamate or its vehicle (culture medium). Solid-phase enzyme-linked immunosorbent assay is used to measure the amount of IL-8 in the supernatant[1].
|
| Animal Protocol |
Mice receive intraperitoneal injections of pyrrolidinedithiocarbamate at doses of 100 and 50 mg/kg. The DSS-treated control group, DSS+pyrrolidinedithiocarbamate-treated groupI (low-dose group), DSS+pyrrolidinedithiocarbamate-treated groupII (high-dose group), and DSS-untreated group (normal group) are all given to mice. Intestinal length, histological score, levels of activated NF-κB and inflammatory cytokines (IL-1β and TNF-α) in tissue, as well as the disease activity index score (DAI score) are all measured in each group[2].
|
| References |
|
| Molecular Formula |
C5H9NS2.H3N
|
|
|---|---|---|
| Molecular Weight |
164.29
|
|
| Exact Mass |
164.04419074
|
|
| Elemental Analysis |
C, 36.56; H, 7.36; N, 17.05; S, 39.03
|
|
| CAS # |
5108-96-3
|
|
| Related CAS # |
|
|
| Appearance |
Solid powder
|
|
| SMILES |
C1CCN(C1)C(=S)[S-].[NH4+]
|
|
| InChi Key |
MDDIUTVUBYEEEM-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C5H9NS2.H3N/c7-5(8)6-3-1-2-4-6;/h1-4H2,(H,7,8);1H3
|
|
| Chemical Name |
azanium;pyrrolidine-1-carbodithioate
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 24 mg/mL (146.08 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.0868 mL | 30.4340 mL | 60.8680 mL | |
| 5 mM | 1.2174 mL | 6.0868 mL | 12.1736 mL | |
| 10 mM | 0.6087 mL | 3.0434 mL | 6.0868 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA